BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12094542)

  • 1. Phase I trial of edatrexate in advanced breast and other cancers.
    Kuriakose P; Gandara DR; Perez EA
    Cancer Invest; 2002; 20(4):473-9. PubMed ID: 12094542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.
    Edelman MJ; Gandara DR; Perez EA; Lau D; Lauder I; Turrell C; Uhrich M; Meyers F
    Invest New Drugs; 1998; 16(1):69-75. PubMed ID: 9740546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
    Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
    J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.
    Moore DF; Pazdur R; Abbruzzese JL; Ajani JA; Dubovsky DW; Wade JL; Belt RJ; Mangold C; Bready B; Winn RJ
    Ann Oncol; 1994 Mar; 5(3):286-7. PubMed ID: 8186177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
    Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
    Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.
    Verma S; Quirt IC; Eisenhauer EA; Iscoe NA; Young VJ; Bodurtha AJ; Davidson J
    Ann Oncol; 1993 Mar; 4(3):254-5. PubMed ID: 8471559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.
    Pazdur R; Moore DF; Bready B; Giannone L; Maldonado A; Lin YG; Fueger RH; Winn RJ; Levin B
    Ann Oncol; 1994 Sep; 5(7):646-8. PubMed ID: 7527654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.
    Schornagel JH; van der Vegt S; Verweij J; de Graeff A; Dullemond-Westland A; van Deijk WA; ten Bokkel Huinink WW
    Ann Oncol; 1992 Jul; 3(7):549-52. PubMed ID: 1498076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
    Gandara DR; Edelman MJ; Crowley JJ; Lau DH; Livingston RB
    Cancer Chemother Pharmacol; 1997; 41(1):75-8. PubMed ID: 9443617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
    Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
    Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edatrexate studies in non-small cell lung cancer.
    Gralla RJ
    Lung Cancer; 1995 Apr; 12 Suppl 1():S187-91. PubMed ID: 7551928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124).
    Meyers FJ; Lew D; Lara PN; Williamson S; Marshall E; Balcerzak SP; Rivkin SE; Samlowski W; Crawford ED
    Invest New Drugs; 1998-1999; 16(4):347-51. PubMed ID: 10426670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of edatrexate in previously treated ovarian cancer. A Gynecologic Oncology Group study.
    Broun ER; Iseminger KA; Bookman M
    Am J Clin Oncol; 1995 Apr; 18(2):164-6. PubMed ID: 7900709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
    Vandenberg TA; Pritchard KI; Eisenhauer EA; Trudeau ME; Norris BD; Lopez P; Verma SS; Buckman RA; Muldal A
    J Clin Oncol; 1993 Jul; 11(7):1241-4. PubMed ID: 8315420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.